certolizumab pegol and rheumatoid arthritis (RA) Archives

Abstract Number: 2451 • ACR/ARHP Annual Meeting 2017
Rapid Onset of Response Observed with Certolizumab Pegol in Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate: Efficacy and Safety Results of a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study
Liqi Bi¹, Yuhui Li², Lan He³, Huji Xu⁴, Jieruo Gu⁵, Guochun Wang⁶, Zhiyi Zhang⁷, Yi Liu⁸, Marion Boehnlein⁹, Jochen Dunkel⁹, Jing Shao¹⁰, Kristina Harris¹¹ and Zhanguo Li¹², ¹China-Japan Union Hospital of Jilin University*, Changchun, China, ²Peking University People’s Hospital*, Beijing, China, ³The First Affiliated Hospital of Xi’an Jiaotong University, Xi'an, China, ⁴Shanghai Changzheng Hospital, Shanghai, China, ⁵Sun Yat-sen University – The Third Affiliated Hospital, Guangzhou, China, ⁶China-Japan Friendship Hospital, Beijing, China, ⁷The First Affiliated Hospital of Harbin Medical University, Harbin, China, ⁸West China Hospital, Sichuan University, Chengdu, China, ⁹UCB Pharma, Monheim, Germany, ¹⁰UCB Pharma, Tokyo, Japan, ¹¹UCB Pharma, Slough, United Kingdom, ¹²Peking University People's Hospital, Beijing, China
Background/Purpose: There are unmet needs for patients (pts) suffering from rheumatoid arthritis (RA) in China, where a limited number of anti-TNFs are available.1, 2 Certolizumab…
Abstract Number: 602 • ACR/ARHP Annual Meeting 2016
Efficacy and Safety of Switching Between Certolizumab Pegol and Adalimumab after Primary Anti-TNF Treatment Failure: 2-Year Results from a Randomized, Investigator-Blind, Superiority Head-to-Head Study
Roy Fleischmann¹, Gerd-Rüdiger Burmester², Bernard Combe³, Jeffrey R. Curtis⁴, Stephen Hall⁵, Boulos Haraoui⁶, Ronald van Vollenhoven⁷, Christopher Cioffi⁸, Cécile Ecoffet⁹, Lucian Ionescu¹⁰, Leon Gervitz¹¹, Luke Peterson⁸ and Josef Smolen¹², ¹University of Texas Southwestern Medical Center at Dallas Metroplex Clinical Research Center, Dallas, TX, ²Charité – University Medicine Berlin, Berlin, Germany, ³Montpellier University Hospital, Montpellier, France, ⁴The University of Alabama at Birmingham, Birmingham, AL, ⁵Cabrini Medical Centre, Monash University, Melbourne, Australia, ⁶Department of Medicine, Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada, ⁷Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, Netherlands, ⁸UCB Pharma, Raleigh, NC, ⁹UCB Pharma, Brussels, Belgium, ¹⁰Allée De La Recherche 60, UCB Pharma, Brussels, Belgium, ¹¹RA Patient Value Mission, UCB Pharma, Brussels, Belgium, ¹²Medical University of Vienna and Hietzing Hospital, Vienna, Austria
Background/Purpose: EULAR, ACR and treat-to-target guidelines recommend switching treatment in inadequate responders (IRs) to alternative therapy by Week (Wk) 12.1-3 Although any biological (b)DMARD can…
Abstract Number: 952 • ACR/ARHP Annual Meeting 2016
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study Evaluating Treatment Strategies (Continuation Versus Withdrawal) for Maintaining Low Disease Activity after 1 Year of Certolizumab Pegol in DMARD-Naive Patients with Early and Progressive, Active RA
Michael Weinblatt¹, Clifton Bingham III², Gerd-Rüdiger Burmester³, Vivian P. Bykerk⁴, Daniel E. Furst⁵, Xavier Mariette⁶, Désirée van der Heijde⁷, Ronald van Vollenhoven⁸, Brenda VanLunen⁹, Cécile Ecoffet¹⁰, Christopher Cioffi⁹ and Paul Emery¹¹, ¹Brigham and Women's Hospital, Boston, MA, ²Johns Hopkins University, Baltimore, MD, ³Charité – University Medicine Berlin, Berlin, Germany, ⁴Divison of Rheumatology, Hospital for Special Surgery, New York, NY, ⁵David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁶Université Paris-Sud, Paris, France, ⁷Leiden University Medical Center, Leiden, Netherlands, ⁸Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, Netherlands, ⁹UCB Pharma, Raleigh, NC, ¹⁰UCB Pharma, Brussels, Belgium, ¹¹University of Leeds, Leeds, United Kingdom
Background/Purpose: There is interest in tapering or stopping biologic DMARD therapy in RA patients (pts) who have achieved sustained disease control.1 We report the results…
Abstract Number: 2987 • ACR/ARHP Annual Meeting 2016
Comparison of Certolizumab Pegol Versus Adalimumab: 2 Year Efficacy and Safety Results from a Superiority, Investigator-Blind, Head-to-Head Study
Roy Fleischmann¹, Gerd-Rüdiger Burmester², Bernard Combe³, Jeffrey R. Curtis⁴, Stephen Hall⁵, Boulos Haraoui⁶, Ronald van Vollenhoven⁷, Christopher Cioffi⁸, Cécile Ecoffet⁹, Lucian Ionescu⁹, Leon Gervitz¹⁰, Luke Peterson⁸ and Josef Smolen¹¹, ¹University of Texas Southwestern Medical Center at Dallas Metroplex Clinical Research Center, Dallas, TX, ²Charité – University Medicine Berlin, Berlin, Germany, ³Montpellier University Hospital, Montpellier, France, ⁴Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Cabrini Medical Centre, Monash University, Melbourne, Australia, ⁶Department of Medicine, Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada, ⁷Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, Netherlands, ⁸UCB Pharma, Raleigh, NC, ⁹UCB Pharma, Brussels, Belgium, ¹⁰RA Patient Value Mission, UCB Pharma, Brussels, Belgium, ¹¹Medical University of Vienna and Hietzing Hospital, Vienna, Austria
Background/Purpose: Head-to-head comparisons of biological (b)DMARDs in the treatment of RA should provide rigorous evidence on the comparative efficacy of different treatments. Although there are…
Abstract Number: 595 • ACR/ARHP Annual Meeting 2016
Cinical Responses and Improvements in Patient-Reported Outcomes Are Associated with Increased Productivity in the Workplace and at Home in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol
Vivian P. Bykerk¹, Paul Emery², Michael Weinblatt³, Gerd-Rüdiger Burmester⁴, Daniel E. Furst⁵, Xavier Mariette⁶, Ronald van Vollenhoven⁷, Oana Purcaru⁸, Pauline Ralston⁹ and Clifton Bingham III¹⁰, ¹Divison of Rheumatology, Hospital for Special Surgery, New York, NY, ²University of Leeds, Midlothian, United Kingdom, ³Brigham and Women’s Hospital, Boston, MA, ⁴Charité – University Medicine Berlin, Berlin, Germany, ⁵David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁶Université Paris-Sud, Paris, France, ⁷Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, Netherlands, ⁸UCB Pharma, Slough, United Kingdom, ⁹Hays Pharma, London, United Kingdom, ¹⁰Johns Hopkins University, Baltimore, MD
Background/Purpose: Rheumatoid arthritis (RA) is associated with work disability, loss of productivity and reduced quality of life. In established and early RA, compared with MTX…
Abstract Number: 968 • ACR/ARHP Annual Meeting 2015
Certolizumab Pegol in Combination with Methotrexate in DMARD-Naïve Patients with Active, Severe, Progressive Rheumatoid Arthritis: Results from a Randomized, Double-Blind, Controlled Phase 3 Study
Michael Weinblatt¹, Clifton Bingham², Gerd Burmester³, VP Bykerk⁴, Daniel E. Furst⁵, Xavier Mariette⁶, Désirée van der Heijde⁷, Daljit Tatla⁸, Catherine Arendt⁹, Irina Mountian¹⁰, Brenda VanLunen¹¹ and Paul Emery¹², ¹Rheumatology Immunology & Allergy, Brigham and Women's Hospital, Boston, MA, ²Johns Hopkins University, Baltimore, MD, ³Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁴Rheumatology, Hospital for Special Surgery, New York, NY, ⁵Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁶Université Paris-Sud, AP-HP, Hôpitaux Universitaires Paris-Sud, Paris, France, ⁷University Hospital, Maastricht, Netherlands, ⁸8010 Arco Corporate Dr, UCB Pharma, Raleigh, NC, ⁹Global Medical Affairs, UCB Pharma, Brussels, Belgium, ¹⁰UCB Pharma, Brussels, Belgium, ¹¹UCB Pharma, Raleigh, NC, ¹²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: Early stages of rheumatoid arthritis (RA) may provide a therapeutic window in which biologic agents are most effective.1 C-EARLY (NCT01519791) is a phase 3…
Abstract Number: 1638 • ACR/ARHP Annual Meeting 2015
Early Response As a Predictor of Long-Term Remission in DMARD-Naïve Patients with Severe, Active and Progressive Rheumatoid Arthritis Treated with Certolizumab Pegol in Combination with Methotrexate
Michael Weinblatt¹, Clifton Bingham², Gerd Burmester³, VP Bykerk⁴, Daniel E. Furst⁵, Xavier Mariette⁶, Désirée van der Heijde⁷, Daljit Tatla⁸, Catherine Arendt⁹, Irina Mountian¹⁰, Brenda VanLunen¹¹ and Paul Emery¹², ¹Rheumatology Immunology & Allergy, Brigham and Women's Hospital, Boston, MA, ²Johns Hopkins University, Baltimore, MD, ³Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁴Hospital for Special Surgery, New York, NY, ⁵Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁶Université Paris-Sud, AP-HP, Hôpitaux Universitaires Paris-Sud, Paris, France, ⁷University Hospital, Maastricht, Netherlands, ⁸8010 Arco Corporate Dr, UCB Pharma, Raleigh, NC, ⁹Global Medical Affairs, UCB Pharma, Brussels, Belgium, ¹⁰UCB Pharma, Brussels, Belgium, ¹¹UCB Pharma, Raleigh, NC, ¹²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: In established rheumatoid arthritis (RA), a lack of response to treatment with certolizumab pegol (CZP) at early timepoints is associated with a low probability…
Abstract Number: 2475 • ACR/ARHP Annual Meeting 2014
Multiple Approaches for Implementation of Long-Term Efficacy: Interpretation of Certolizumab Pegol Data in Rheumatoid Arthritis Case Study
Edward C. Keystone¹, Josef Smolen², Vibeke Strand³, Thomas Kumke⁴, Irina Mountian⁵, Susan Walker⁶ and Robert B. M. Landewé^7,8, ¹University of Toronto, Mount Sinai Hospital, Toronto, ON, Canada, ²Division of Rheumatology, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ³Biopharmaceutical Consultant, Portola Valley, CA, ⁴UCB Pharma, Monheim, Germany, ⁵UCB Pharma, Brussels, Belgium, ⁶UCB Pharma, Raleigh, NC, ⁷Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ⁸Atrium Medical Center, Heerlen, Netherlands
Background/Purpose Use of imputed or observed data, as well as the patient (pt) population evaluated (eg. intention-to-treat [ITT], completer), affects the interpretation of long-term efficacy…
Abstract Number: 1844 • ACR/ARHP Annual Meeting 2014
Identification of a Patient Phenotype Which Impacts Response to Therapy in Rheumatoid Arthritis Clinical Trials: Certolizumab Pegol Phase 4 Trial Data
Jeffrey R. Curtis¹, Melvin Churchill², Alan Kivitz³, Laura Gauer⁴, Christopher Herrem⁴, David Carter⁵, Jeffrey Melin⁴ and Yusuf Yazici⁶, ¹The University of Alabama at Birmingham, Birmingham, AL, ²Arthritis Center of Nebraska, Lincoln, NE, ³Altoona Arthritis & Osteoporosis Center, Duncansville, PA, ⁴UCB Pharma, Smyrna, GA, ⁵UCB Pharma, Brussels, Belgium, ⁶New York University Hospital for Joint Diseases, New York, NY
Background/Purpose The PREDICT trial (NCT01255761) examined predictability of certolizumab pegol (CZP) treatment success at Week (Wk) 52 based on response at Wk12 assessed by RAPID3…
Abstract Number: 2322 • ACR/ARHP Annual Meeting 2013
Post–Hoc Analysis Showing Better Clinical Response With The Loading Dose Of Certolizumab Pegol In Japanese Patients With Active Rheumatoid Arthritis
Tsutomu Takeuchi¹, Kazuhiko Yamamoto^2,3, Hisashi Yamanaka⁴, Naoki Ishiguro⁵, Yoshiya Tanaka⁶, Katsumi Eguchi⁷, Akira Watanabe⁸, Hideki Origasa⁹, Mariko Kobayashi¹⁰, Toshiharu Shoji¹⁰, Nobuyuki Miyasaka¹¹ and Takao Koike¹², ¹Department of Rheumatology, Keio University, Tokyo, Japan, ²Department of Allergy and Rhaumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ³University of Tokyo, Tokyo, Japan, ⁴Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁵Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ⁶The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁷Sasebo City General Hospital, Sasebo, Nagasaki, Japan, ⁸Tohoku University, Sendai, Japan, ⁹Division of Biostatistics and Clinical Epidemiology, University of Toyama School of Medicine, Toyama, Toyama, Japan, ¹⁰UCB Pharma, Tokyo, Japan, ¹¹Tokyo Medical and Dental University, Tokyo, Japan, ¹²Rheumatology, NTT Sapporo Medical Center, Sapporo, Japan
Background/Purpose: Certolizumab pegol (CZP) with MTX (J-RAPID; NCT00791999) and without MTX (HIKARI; NCT00791921) has demonstrated rapid and sustained improvements in disease activity in Japanese patients…
Abstract Number: 2323 • ACR/ARHP Annual Meeting 2013
Comprehensive Disease Remission Achieved By Certolizumab Pegol Treatment, and Factors Associated With Certolizumab Pegol Comprehensive Disease Remission, In Rheumatoid Arthritis Patients With Predominantly High Disease Activity
Yoshiya Tanaka¹, Kazuhiko Yamamoto², Tsutomu Takeuchi³, Hisashi Yamanaka⁴, Naoki Ishiguro⁵, Katsumi Eguchi⁶, Akira Watanabe⁷, Hideki Origasa⁸, Tadao Okamoto⁹, Yumiko Wada⁹, Toshiharu Shoji⁹, Nobuyuki Miyasaka¹⁰ and Takao Koike¹¹, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²Department of Allergy and Rheumatology, The University of Tokyo, Tokyo, Japan, ³Keio University, Tokyo, Japan, ⁴Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁵Department of Orthopedic Surgery, Nagoya University, Nagoya, Japan, ⁶Sasebo City General Hospital, Sasebo, Japan, ⁷Tohoku University, Sendai, Japan, ⁸Division of Biostatistics and Clinical Epidemiology, University of Toyama School of Medicine, Toyama, Toyama, Japan, ⁹UCB Pharma, Tokyo, Japan, ¹⁰Department of Medicine and Rheumatology, Graduate School of Medicine and Dentistry, Tokyo Medical and Dental University, Tokyo, Japan, ¹¹NTT Sapporo Medical Center, Sapporo, Japan
Background/Purpose: The therapeutic goals of treating rheumatoid arthritis (RA) are clinical, structural and functional remissions.1,2 Simultaneously achieving all three has been referred to as comprehensive…
Abstract Number: 1976 • ACR/ARHP Annual Meeting 2013
Magnetic Resonance Imaging-Assessment Of Early Response To Certolizumab Pegol In Rheumatoid Arthritis: A Randomized, Double-Blind, Placebo-Controlled Phase IIIb Study Applying Magnetic Resonance Imaging At Week 0, 1, 2, 4, 8 and 16
Mikkel Ostergaard¹, Lennart Jacobsson², Christopher Schaufelberger³, Michael Sejer-Hansen⁴, Johannes Bijlsma⁵, Anna Dudek⁶, Maria Rell-Bakalarska⁷, Fabienne Staelens⁸, Robert Haake⁹, Britt Sundman-Engberg¹⁰ and Henning Bliddal¹¹, ¹Copenhagen Center for Arthritis Research, Glostrup, Denmark, ²Department of Clinical Sciences, Section of Rheumatology, Malmö, Sweden, ³Department of Rheumatology & Inflammation Research, Sahlgrens' Hospital, Göteborg, Sweden, ⁴Rheumatology Clinic, Copenhagen, Denmark, ⁵Deptartment of Rheumatology & Immunity, University Medical Center, Utrecht, Netherlands, ⁶Medica Pro Familia, Warsaw, Poland, ⁷Rheuma Medicus, Warsaw, Poland, ⁸UCB Pharma, Brussels, Belgium, ⁹UCB Pharma, Raleigh, NC, ¹⁰UCB Pharma, Stockholm, Sweden, ¹¹Department of Rheumatology, The Parker Institute, Frederiksberg, Denmark
Background/Purpose: The OMERACT rheumatoid arthritis (RA) magnetic resonance imaging (MRI) scoring system (RAMRIS) is a validated scoring system for assessment of synovitis, bone edema and…

Abstracts tagged "certolizumab pegol and rheumatoid arthritis (RA)"